Also found in: Medical, Encyclopedia, Wikipedia.
Related to macroglobulinemia: Waldenstrom's macroglobulinemia


A condition marked by an abnormally high concentration of macroglobulins in the blood serum.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
References in periodicals archive ?
Detection of monoclonal IgM in the serum is typical in LPL, and monoclonal serum IgM combined with the presence of LPL in the bone marrow defines the clinicopathologic entity of Waldenstrom macroglobulinemia. (49) However, marginal zone lymphomas and other B-cell lymphoproliferative disorders may be associated with an IgM paraprotein, so this finding alone is not fully discriminatory.
IgM paraproteinemia is seen in Waldenstrom macroglobulinemia, B-cell lymphoma or lymphoproliferative disorders, monoclonal gammopathy of undermined significance (MGUS), [mu]-heavy chain disease, and IgM myeloma.
BeiGene announced updated results from the Phase 1 clinical trial of its investigational BTK inhibitor zanubrutinib, in an oral presentation at the 10th International Workshop on Waldenstrom's Macroglobulinemia. The IWWM meeting is taking place in New York City from October 11-13, 2018.
M2 PHARMA-December 7, 2017-Janssen's Phase three iNNOVATE study indicates improved progression-free survival in Waldenstrom macroglobulinemia patients
M2 EQUITYBITES-January 30, 2015-Pharmacyclics announces first and only US FDA's approval of IMBRUVICA for Waldenstrom's macroglobulinemia
However, CD5 can occasionally be expressed by other small B-cell neoplasms, such as MZL of various types and, less often, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/ WM), follicular lymphoma, and other less-frequent small Bcell neoplasms.
Both patients were known to have Waldenstrom macroglobulinemia (IgM-[kappa] type).
Food and Drug Administration for the treatment of patients with Waldenstrom macroglobulinemia. BeiGene plans to submit an NDA to the FDA for zanubrutinib as a potential treatment for patients with WM in the first half of 2019 based on results from a global Phase 1 study.
B-cell malignancies, like chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, DLBCL and mantle cell lymphoma are driven by BTK.
The European Medicines Agency has received a Type II variation application from Belgium-based Janssen-Cilag International to include a new therapeutic indication for Imbruvica to treat adults with Waldenstrom's macroglobulinemia, it was reported yesterday.